Shire Aims To Stay On Top In Hemophilia With Novimmune Pact

 
• By Kevin Grogan

Having become embroiled in a legal tussle with Roche last week concerning the latter's emicizumab, Shire has licensed a hemophilia A bispecific monoclonal antibody of its own.

RedBloodCellsOnWhite_1200x675
Shire gets a bi-specific mAb for hemophilia A of its own • Source: Shutterstock

More from Blood and Clotting

More from Therapy Areas